Boston Sci., St. Jude settle patent suits
This article was originally published in The Gray Sheet
Executive Summary
Both firms appear to benefit from a settlement that resolves four patent disputes related to the firms' cardiac rhythm management and neuromodulation devices. According to the July 31 announcement, the companies also have reached an accord to limit legal parameters for two additional suits, one of which dates back to 1996 (1"The Gray Sheet" Feb. 18, 2002, In Brief). The agreement bars Boston Scientific from pursuing lost profits and caps royalties at 3% of revenue from sales found to have infringed the patent in question. The companies agreed to cross-license certain of their cardiac rhythm management and neuromodulation patents. St. Jude describes the cross-license agreements as "worldwide" and "royalty free" in a filing with the Securities & Exchange Commission...
You may also be interested in...
Guidant v. St. Jude
Overturned $140 mil. implantable cardiac defibrillator patent infringement damage award to Guidant will likely be appealed, according to St. Jude. Filed by Guidant in November 1996 in Indianapolis federal court, the complaint currently focuses on two Guidant ICD patents ('472 and '288). Judge David Hamilton ruled Feb. 13 that "both patents are invalid," St. Jude says. A jury awarded Guidant the damages in July 2001, after finding that St. Jude infringed the '472 patent, which expired March 4, but that it did not infringe the '288 patent; both had been ruled valid (1"The Gray Sheet" July 9, 2001, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.